A carregar...
Anti-CD20 monoclonal antibodies: historical and future perspectives
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2805725/ https://ncbi.nlm.nih.gov/pubmed/19773256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2008.001628 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|